Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

X
Search
Drug Profile

AL 0670

Latest Information Update: 26 Feb 2001

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Class Antihypertensives
  • Mechanism of Action Potassium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Hypertension

Most Recent Events

  • 26 Feb 2001 Profile reviewed but no significant changes made
  • 10 Jul 1998 No-Development-Reported for Hypertension in Japan (Unknown route)
  • 10 May 1995 New profile

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days

Latest webinar now available!

Our latest webinar, Navigating the Complex Landscape of Clinical Trials: Trends, Global Impact, including Hits & Misses 2024, is available now. Key topics include an analysis of trials with both positive and negative outcomes, failed trials of 2024, and impactful trials of 2024 that contributed to regulatory approvals or company revenue, followed by an outlook on a few pivotal trials to watch in 2025.

Watch here!